bioRxivMicrobiologyPreprint
40 minutes RT-qPCR Assay for Screening Spike N501Y and HV69-70del Mutations
G. Korukluoglu, M. Kolukirik, F. Bayrakdar, G. G. Ozgumus, A. B. Altas, Y. Cosgun, C. Z. Ketre Kolukirik
Abstract
A one-step reverse transcription and real-time PCR (RT-qPCR) test was developed for rapid screening (40 minutes) of the Spike N501Y and HV69-70del mutations in SARS-CoV-2 positive samples. The test also targets a conserved region of SARS-CoV-2 Orf1ab as an internal control. The samples containing both the N501Y and HV69-70del mutations are concluded as VOC-202012/01 positive. Samples suspected to be positive for B.1.351 or P.1 are the N501Y positive and HV69-70del negative cases. Limit of detection (LOD) of the kit for Orf1ab target is 500 copies/mL, while that of the N501, Y501 and HV69-70del targets are 5000 copies/mL. The developed assay was applied to 165 clinical samples containing SARS-CoV-2 from 32 different lineages. The SARS-CoV-2 lineages were determined via the next-generation sequencing (NGS). The RT-qPCR results were in 100% agreement with the NGS results that 19 samples were N501Y and HV69-70del positive, 10 samples were N501Y positive and HV69-70del negative, 1 sample was N501Y negative and HV69-70del positive, and 135 samples were N501Y and HV69-70del negative. All the VOC-202012/01 positive samples were detected in people who have traveled from England to Turkey. The RT-qPCR test and the Sanger sequencing was further applied to 1000 SARS-CoV-2 positive clinical samples collected in Jan2021 from the 81 different provinces of Turkey. The RT-qPCR results were in 100% agreement with the Sanger sequencing results that 32 samples were N501Y positive and HV69-70del negative, 4 samples were N501Y negative and HV69-70del positive, 964 samples were N501Y and HV69-70del negative. The specificity of the 40 minutes RT-qPCR assay relative to the sequencing-based technologies is 100%. The developed assay is an advantageous tool for timely and representative estimation of the N501Y positive variants prevalence because it allows testing a much higher portion of the SARS-CoV-2 positives in much lower time compared to the sequencing-based technologies.
- assay: bulk RNA-seq
- research focus: host-pathogen & immune response
- research focus: variant calling
- research focus: benchmarking
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Design of a Novel Multiplex Real Time RT-PCR Assay for SARS-CoV-2 Detection
W. Zhen, G. J. Berry·bioRxiv·Jun 4, 2020
- Detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a fourplex real-time quantitative reverse transcription-PCR assays.
Mathieu Durand, Philippe Thibault, … Simon Labbé·Microbial CellPeer-reviewed·Dec 28, 2021
- Neutralization of spike 69/70 deletion, E484K, and N501Y SARS-CoV-2 by BNT162b2 vaccine-elicited sera
- Y380Q novel mutation in receptor-binding domain of SARS-CoV-2 spike protein together with C379W interfere in the neutralizing antibodies interaction
Ivaine Taís Sauthier Sartor, Fernanda Hammes Varela, … COVIDa study group·Diagnostic Microbiology and Infectious DiseasePeer-reviewed·Jan 16, 2022
- Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera
- Evaluation of the effects of SARS-CoV-2 genetic mutations on diagnostic RT-PCR assays
Takeru Nakabayashi, Yuki Kawasaki, … Satoshi Yuhara·bioRxiv·Jan 19, 2021